Chongqing Genrix Biopharmaceutical Co., Ltd.SSE: 688443

Preliminary Earnings Estimate for 2024

Feb 28, 2025 · Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Feb 28, 2025

On 6ix: 6ix.com/news/preliminary-earnings-estimate-for-2024-16

Preliminary Earnings Estimate for 2024

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Chongqing Genrix Biopharmaceutical Co., Ltd. on 6ix

Earlier from Chongqing Genrix Biopharmaceutical

Announcement on the Voluntary Disclosure Regarding the Initiation of Phase III Clinical Trial for GR1802 Injection in the Indication of Chronic Spontaneous UrticariaFeb 14, 2025
Voluntary Disclosure Announcement on the Approval of Marketing Application for New Indications of XeligekimabJan 21, 2025
Annual Earnings Preannouncement for 2024Jan 18, 2025
Announcement on Voluntary Disclosure on the Acceptance of New Drug Application for Silevimig InjectionJan 15, 2025
Announcement on Completing General Election of Board of Directors and Board of Supervisors, and Appointing Senior Management Members, Head of Internal Audit Department and Securities Affairs RepresentativeDec 25, 2024

Later from Chongqing Genrix Biopharmaceutical

Notice on Convening the 2024 Annual General MeetingApr 26, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance BriefingMay 20, 2025
Announcement on Voluntary Disclosure on the Acceptance of New Drug Application for GR2001 InjectionMay 23, 2025
Announcement on Initial Public Offering of Restricted Shares under Strategic Allotment for CirculationJun 13, 2025
Announcement on Resolutions of the 2024 Annual General MeetingJun 19, 2025

All Chongqing Genrix Biopharmaceutical news releases

Follow Chongqing Genrix Biopharmaceutical into a list and get an email when it puts out news.

Follow Chongqing Genrix Biopharmaceutical